Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer

Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer

Bibliographic Details
Main Authors:	Rea, D, Gray, R, Bowden, S, Handley, K, Earl, H, Poole, C, Bates, T, Dewar, J, Raytor, Z, Lee, M
Format:	Conference item
Published:	2013

Similar Items

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
by: Dennis C. Sgroi, et al.
Published: (2022-12-01)

An Extraordinary New Toad (Bufo) ttom Costa Rica
by: Jay M Savage
Published: (2002-06-01)

Tamoxifen-independent recombination in the RIP-CreER mouse.
by: Yanmei Liu, et al.
Published: (2010-10-01)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
by: Emily K. Zboril, et al.
Published: (2023-06-01)

Testing the untestable in language education /
by: Paran, Amos, et al.
Published: (c201)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
by: Qing Lv MD, PhD, et al.
Published: (2021-03-01)

Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals
by: Joonatan Palmu, et al.
Published: (2020-08-01)

Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer
by: Ho Tsoi, et al.
Published: (2022-02-01)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
by: Liu Y, et al.
Published: (2020-08-01)

CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance.
by: Tian Gao, et al.
Published: (2014-01-01)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
by: Aggeliki K. Meligova, et al.
Published: (2023-02-01)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
by: Yan Xiu Ouyang, et al.
Published: (2021-06-01)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα+ breast cancer
by: Coralie Poulard, et al.
Published: (2023-08-01)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
by: Javier A. Menendez, et al.
Published: (2021-03-01)

A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastia
by: Weili He, et al.
Published: (2023-03-01)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
by: Hyunhee Kim, et al.
Published: (2021-05-01)

Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer
by: Ho Tsoi, et al.
Published: (2022-10-01)

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer
by: Angela Maselli, et al.
Published: (2019-07-01)

Dynamic surveillance of tamoxifen‐resistance in ER‐positive breast cancer by CAIX‐targeted ultrasound imaging
by: Ying Li, et al.
Published: (2020-04-01)

A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER− cells via endoplasmic reticulum stress-induced apoptosis
by: Tinglin Yang, et al.
Published: (2024-02-01)

Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.
by: Li Yin, et al.
Published: (2014-01-01)

ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
by: Anieta M. Sieuwerts, et al.
Published: (2020-03-01)

ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
by: Anieta M. Sieuwerts, et al.
Published: (2020-03-01)

Five years of tamoxifen--or more?
by: Peto, R
Published: (1996)

Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer
by: Vasiliki Vafeiadou, et al.
Published: (2022-02-01)

Limitations of Tamoxifen Application for In Vivo Genome Editing Using Cre/ER<sup>T2</sup> System
by: Leonid A. Ilchuk, et al.
Published: (2022-11-01)

FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
by: Lukasz Turczyk, et al.
Published: (2017-10-01)

δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer.
by: Shaocong Guo, et al.
Published: (2012-01-01)

Highlights of the first twenty years of the ERS, 1990-2010 past presidents of the ERS recall activities during their term of office
by: Donner Claudio F
Published: (2010-02-01)

Peculiarities of gastroduodenal pathology in children in the families of parents with untested dyspepsia
by: V. V. Tsukanov, et al.
Published: (2019-07-01)

Diallel analysis and prediction of untested maize single cross hybrids
by: José Lidércio Matias Júnior, et al.
Published: (2019-02-01)

Importance of untested infectious individuals for interventions to suppress COVID-19
by: Francisco J. Pérez-Reche, et al.
Published: (2021-10-01)

ASCLD statement on volume of untested sexual assault evidence kits
by: Laura Sudkamp, et al.
Published: (2020-01-01)

ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
by: Sheng-Li Lin, et al.
Published: (2010-02-01)

ERβ Isoforms Have Differential Clinical Significance in Breast Cancer Subtypes and Subgroups
by: Young Choi, et al.
Published: (2022-04-01)

Video er TV er video
by: Susanna Neimann
Published: (1988-08-01)

Video er TV er video
by: Susanna Neimann
Published: (1988-08-01)

SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer
by: Ho Tsoi, et al.
Published: (2023-04-01)

NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
by: Yu Cheon Kim, et al.
Published: (2021-06-01)

circRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells
by: Zheng Li, et al.
Published: (2023-07-01)